Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130742 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL14617186 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL14617185 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL25849269 | 0.98 | CNR1 (0.44) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL20127926 | 0.98 | CNR1 (0.44) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL16359217 | 0.95 | LPAR2 (0.44) | TRPV1 | |
| SCHEMBL129777 | 0.91 | ALDH1A1 (0.41) | ALDH1A1CNR1CNR2 | |
| SCHEMBL25849270 | 0.91 | ALDH1A1 (0.41) | ALDH1A1CNR1CNR2 | |
| SCHEMBL131835 | 0.90 | CNR1 (0.40) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL129695 | 0.90 | CNR1 (0.40) | ALDH1A1CNR1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-9764036-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-09-19 | — | — | US | disclosed |
| US-20160317676-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-11-03 | — | — | US | disclosed |
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-07-28 | — | — | US | disclosed |
| US-8722082-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-05-13 | — | — | US | disclosed |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213785-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | ALDH1A1 3880/4885CNR1 1857/4885CNR2 1808/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885 |
| US-20120058144-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ABCB4, CETP, SGMS1 | ALDH1A1 3777/4885CNR1 2763/4885CNR2 2760/4885 |
| US-20160317676-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | LIPA, APOB, LIPC | ALDH1A1 4338/4885CNR1 3995/4885CNR2 3641/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | ALDH1A1 4484/4885CNR1 4579/4885CNR2 4780/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | ALDH1A1 4532/4885CNR1 4492/4885CNR2 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.